Pralsetinib vs Vepafestinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: RET · full Non-Small Cell Lung Cancer pipeline

Pralsetinib

Marketed by Rigel Pharmaceuticals and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04222972 · Phase 3 · terminated

This was a randomized, active-controlled trial in 223 patients that met its primary progression-free-survival endpoint with a clear statistical result, but it was conducted open-label (patients and investigators knew which treatment was given), which limits confidence in an investigator-assessed endpoint like progression.

Next expected readout: November 2026 · NCT04302025 (registry estimate)

Reported efficacy

Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5) (met)

Result source: NCT04222972

Vepafestinib

Developed by Taiho Pharmaceutical

Phase 1/2 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2030 · NCT04683250 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPralsetinibVepafestinib
PFS, median18.7 vs 9vs SOCn 110NCT04222972
6 other results
—Not reported
OS, median39.7bn 141NCT03037385
4 other results
—Not reported
ORR65.5% vs 41.6%vs SOCn 110NCT04222972
18 other results
—Not reported
Duration of response, median20.6 vs 9.7vs SOCn 72NCT04222972
7 other results
—Not reported

PFS, median

Pralsetinib
18.7 vs 9vs SOCn 110NCT04222972
6 other results
Vepafestinib
—Not reported

OS, median

Pralsetinib
39.7bn 141NCT03037385
4 other results
Vepafestinib
—Not reported

ORR

Pralsetinib
65.5% vs 41.6%vs SOCn 110NCT04222972
18 other results
Vepafestinib
—Not reported

Duration of response, median

Pralsetinib
20.6 vs 9.7vs SOCn 72NCT04222972
7 other results
Vepafestinib
—Not reported
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Vepafestinib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Pralsetinib: 3 of 4 rows · Vepafestinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPralsetinib
Dropout rate
n/a: no completion milestonea
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 10 more results
n/a: no completion milestone400 mg
NCT03037385 · Phase 1/2
—400 mg QD
NCT03037385 · Phase 1/2
n/a: no completion milestone600 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone300 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone200 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone200/100 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone100 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone100/100 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone60 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone30 mg
NCT03037385 · Phase 1/2
Discontinued due to AEs
0.9%a
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 10 more results
0%400 mg
NCT03037385 · Phase 1/2
—400 mg QD
NCT03037385 · Phase 1/2
0%600 mg
NCT03037385 · Phase 1/2
0%300 mg
NCT03037385 · Phase 1/2
0%200 mg
NCT03037385 · Phase 1/2
0%200/100 mg
NCT03037385 · Phase 1/2
20%100 mg
NCT03037385 · Phase 1/2
0%100/100 mg
NCT03037385 · Phase 1/2
0%60 mg
NCT03037385 · Phase 1/2
0%30 mg
NCT03037385 · Phase 1/2
Serious AEs
62%a
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 10 more results
—400 mg
NCT03037385 · Phase 1/2
70.6%400 mg QD
NCT03037385 · Phase 1/2
—600 mg
NCT03037385 · Phase 1/2
—300 mg
NCT03037385 · Phase 1/2
—200 mg
NCT03037385 · Phase 1/2
—200/100 mg
NCT03037385 · Phase 1/2
—100 mg
NCT03037385 · Phase 1/2
—100/100 mg
NCT03037385 · Phase 1/2
—60 mg
NCT03037385 · Phase 1/2
—30 mg
NCT03037385 · Phase 1/2
Most frequent reported AEs
a
anaemia 48.1%
constipation 43.5%
aspartate aminotransferase increased 41.7%
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
400 mg QD
anaemia 52.8%
aspartate aminotransferase increased 50.6%
constipation 44.1%
NCT03037385 · Phase 1/2

Notes

  1. aPopulation comparability has not been reviewed for 10 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pralsetinib

PFS 18.7 vs 9 SOC months
time to event · months
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
ORR 65.5% (n=110) vs 41.6% (n=113) SOC
responder rate · % of participants
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Overall Survival NA vs 39.8 SOC months
time to event · months
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Duration of Response 20.6 vs 9.7 SOC months
time to event · months
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Clinical Benefit 74.5% (n=110) vs 58.4% (n=113) SOC
responder rate · % of participants
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Disease Control 88.2% (n=110) vs 79.6% (n=113) SOC
responder rate · % of participants
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
ORR 41.7% (n=12)400 mg
responder rate · % of participants
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 17 more results
25% (n=4)600 mg
NCT03037385 · Phase 1/2
45.5% (n=11)300 mg
NCT03037385 · Phase 1/2
38.5% (n=13)200 mg
NCT03037385 · Phase 1/2
75% (n=4)200/100 mg
NCT03037385 · Phase 1/2
40% (n=5)100 mg
NCT03037385 · Phase 1/2
80% (n=5)100/100 mg
NCT03037385 · Phase 1/2
50% (n=6)60 mg
NCT03037385 · Phase 1/2
0% (n=2)30 mg
NCT03037385 · Phase 1/2
63.1% (n=130)
NCT03037385 · Phase 1/2
73.9% (n=23)
NCT03037385 · Phase 1/2
78.3% (n=106)
NCT03037385 · Phase 1/2
56.7% (n=60)
NCT03037385 · Phase 1/2
77.8% (n=72)
NCT03037385 · Phase 1/2
85.2% (n=27)
NCT03037385 · Phase 1/2
46.4% (n=28)
NCT03037385 · Phase 1/2
19% (n=21)
NCT03037385 · Phase 1/2
7.7% (n=13)
NCT03037385 · Phase 1/2
Duration of Response 31.8 months
time to event · months
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 8 more results
22.6 months
NCT03037385 · Phase 1/2
13.4 months
NCT03037385 · Phase 1/2
21.7 months
NCT03037385 · Phase 1/2
51.8 months
NCT03037385 · Phase 1/2
NA months
NCT03037385 · Phase 1/2
11.1 months
NCT03037385 · Phase 1/2
NA months
NCT03037385 · Phase 1/2
5.5 months
NCT03037385 · Phase 1/2
Clinical Benefit 74.6% (n=130)
responder rate · % of participants
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 8 more results
78.3% (n=23)
NCT03037385 · Phase 1/2
80.2% (n=106)
NCT03037385 · Phase 1/2
80% (n=60)
NCT03037385 · Phase 1/2
90.3% (n=72)
NCT03037385 · Phase 1/2
85.2% (n=27)
NCT03037385 · Phase 1/2
60.7% (n=28)
NCT03037385 · Phase 1/2
28.6% (n=21)
NCT03037385 · Phase 1/2
23.1% (n=13)
NCT03037385 · Phase 1/2
Disease Control 91.5% (n=130)
responder rate · % of participants
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 8 more results
91.3% (n=23)
NCT03037385 · Phase 1/2
89.6% (n=106)
NCT03037385 · Phase 1/2
95% (n=60)
NCT03037385 · Phase 1/2
93.1% (n=72)
NCT03037385 · Phase 1/2
96.3% (n=27)
NCT03037385 · Phase 1/2
75% (n=28)
NCT03037385 · Phase 1/2
42.9% (n=21)
NCT03037385 · Phase 1/2
69.2% (n=13)
NCT03037385 · Phase 1/2
PFS 16.4 months
time to event · months
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 6 more results
13 months
NCT03037385 · Phase 1/2
12.1 months
NCT03037385 · Phase 1/2
24.9 months
NCT03037385 · Phase 1/2
55.3 months
NCT03037385 · Phase 1/2
NA months
NCT03037385 · Phase 1/2
7 months
NCT03037385 · Phase 1/2
Overall Survival 39.7 months
time to event · months
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 6 more results
46 months
NCT03037385 · Phase 1/2
50.1 months
NCT03037385 · Phase 1/2
42.2 months
NCT03037385 · Phase 1/2
NA months
NCT03037385 · Phase 1/2
NA months
NCT03037385 · Phase 1/2
10.3 months
NCT03037385 · Phase 1/2

+ 4 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pralsetinib's landscape · Vepafestinib's landscape